Supplementary Table 1A Validation of Pheno-Group 1 by Comparison Between Full Sample And

Supplementary Table 1A – Validation of pheno-group 1 by comparison between full sample and five 80% resampling subsets

Clinical characteristics / Full pheno-group
(N=892) / Resample 1
(N=707) / Resample 2
(N=699) / Resample 3
(N=792) / Resample 4
(N=721) / Resample 5
(N=705) / P value
Age, years / 56±11 / 56±11 / 56±11 / 56±11 / 56±11 / 55±11 / NS
Females, n(%) / 532 (60) / 413 (58) / 418 (60) / 471 (59) / 435 (60) / 412 (58) / NS
African American, n(%) / 408 (46) / 314 (44) / 317 (45) / 382 (48) / 331 (46) / 332 (47) / NS
Systolic blood pressure, mmHg / 133±20 / 133±21 / 133±21 / 134±20 / 133±21 / 133±21 / NS
Diastolic blood pressure, mmHg / 74±11 / 74±11 / 74±11 / 74±12 / 74±11 / 74±12 / NS
Coronary artery disease, n(%) / 91 (10) / 69 (10) / 72 (10) / 87 (11) / 66 (9) / 68 (10) / NS
Diabetes, n(%) / 169 (19) / 124 (18) / 119 (17) / 171 (22) / 134 (19) / 124 (18) / NS
Smoking history, n(%) / 400 (45) / 324 (46) / 323 (47) / 356 (45) / 313 (44) / 323 (46) / NS
BMI, kg/m2 / 31±6 / 31±6 / 31±6 / 32±7 / 31±6 / 31±6 / NS
GFR, ml/min/1.73m2 / 82±19 / 82±19 / 82±19 / 84±20 / 83±19 / 83±19 / NS
Glucose, mg/dL / 105±26 / 103±22 / 103±24 / 108±35 / 104±25 / 103±23 / <0.001
HOMA-IR / 2.4±1.74 / 2.31±1.62 / 2.32±1.62 / 2.71±2.25 / 2.41±1.73 / 2.28±1.57 / <0.001
LDL cholesterol, mg/dL / 123±33 / 122±33 / 122±33 / 123±33 / 122±33 / 123±33 / NS
HDL cholesterol, mg/dL / 50±15 / 51±15 / 51±15 / 50±15 / 51±16 / 51±15 / NS
Triglycerides, mg/dL / 149±92 / 145±86 / 150±94 / 148±92 / 149±94 / 147±92 / NS
Uric acid, mg/dL / 6.01±1.48 / 5.99±1.47 / 6.01±1.53 / 6.06±1.55 / 5.99±1.48 / 5.98±1.49 / NS
Urine sodium, mmol/L / 105±53 / 104±52 / 106±52 / 106±52 / 105±53 / 106±54 / NS
Urine potassium, mmol/L / 32±18 / 32±19 / 32±18 / 32±18 / 31±18 / 32±19 / NS
Anti-hypertensive medication, n(%) / 788 (88) / 615 (87) / 614 (88) / 690 (87) / 637 (89) / 617 (88) / NS
Beta blocker / 210 (24) / 156 (22) / 167 (24) / 186 (24) / 168 (23) / 155 (22) / NS
Calcium channel blocker / 342 (38) / 269 (38) / 270 (39) / 298 (38) / 280 (39) / 262 (37) / NS
Angiotensin II receptor blocker / 40 (4) / 29 (4) / 34 (5) / 31 (4) / 29 (4) / 34 (5) / NS
Angiotensin converting enzyme inhibitor / 296 (33) / 233 (33) / 231 (33) / 283 (36) / 247 (34) / 241 (34) / NS
Thiazide diuretic / 179 (20) / 135 (19) / 138 (20) / 153 (19) / 143 (20) / 146 (21) / NS
Sympatholytic / 110 (12) / 91 (13) / 84 (12) / 96 (12) / 82 (11) / 85 (12) / NS
Statin, n(%) / 96 (11) / 73 (10) / 76 (11) / 82 (10) / 79 (11) / 74 (11) / NS
Conventional echocardiographic characteristics
LV end diastolic volume, ml / 128±26 / 130±27 / 128±26 / 130±29 / 127±26 / 129±26 / NS
LV end systolic volume, ml / 49±15 / 49±16 / 48±15 / 50±17 / 48±15 / 48±15 / NS
LV ejection fraction, % / 63±6 / 63±6 / 63±6 / 62±7 / 63±6 / 63±6 / NS
LV mass index, g/m2 / 88±17 / 88±17 / 87±17 / 89±18 / 87±17 / 88±17 / NS
LV hypertrophy, n(%) / 164 (19) / 128 (19) / 130 (19) / 161 (21) / 136 (19) / 129 (19) / NS
LV mass/volume ratio / 1.35±0.21 / 1.35±0.22 / 1.36±0.2 / 1.37±0.22 / 1.36±0.21 / 1.35±0.21 / NS
Left atrial dimension, cm / 3.57±0.49 / 3.57±0.49 / 3.56±0.49 / 3.59±0.5 / 3.57±0.51 / 3.54±0.48 / NS
Stroke volume, ml / 78±15 / 79±15 / 78±15 / 79±16 / 79±15 / 79±15 / NS
Cardiac index, L/min/m2 / 2.7±0.6 / 2.7±0.6 / 2.6±0.5 / 2.7±0.6 / 2.7±0.6 / 2.7±0.6 / NS
Pulse pressure/stroke volume, mmHg/ml / 0.75±0.23 / 0.75±0.23 / 0.75±0.23 / 0.75±0.24 / 0.74±0.23 / 0.74±0.22 / NS
E velocity, cm/s / 66±20 / 65±19 / 66±20 / 66±20 / 67±20 / 65±19 / NS
A velocity, cm/s / 71±19 / 69±18 / 70±19 / 71±20 / 71±20 / 70±19 / NS
E/A ratio / 0.98±0.37 / 0.97±0.33 / 0.97±0.36 / 0.98±0.41 / 1.00±0.39 / 0.97±0.29 / NS
Mitral valve deceleration time, ms / 208±58 / 208±59 / 205±55 / 211±62 / 207±57 / 206±57 / NS
Isovolumic relaxation time, ms / 83±18 / 83±18 / 83±18 / 83±18 / 83±19 / 83±18 / NS
Wall motion abnormality, n(%) / 26 (3) / 21 (3) / 21 (3) / 37 (5) / 22 (3) / 23 (3) / NS
Cardiac mechanics
Absolute longitudinal strain, % / 15±4 / 15±3 / 15±4 / 14±4 / 15±4 / 15±3 / NS
Absolute circumferential strain, % / 21±6 / 21±6 / 21±6 / 21±6 / 21±6 / 21±6 / NS
Radial strain, % / 27±12 / 27±12 / 27±12 / 26±12 / 27±12 / 27±12 / NS
e’ velocity, cm/s / 3.32±1.1 / 3.37±1.07 / 3.33±1.11 / 3.32±1.14 / 3.31±1.1 / 3.37±1.12 / NS
E/e’ ratio / 23±11 / 22±10 / 23±11 / 24±11 / 23±11 / 22±10 / NS
Early diastolic strain rate, s-1 / 0.78±0.22 / 0.78±0.22 / 0.78±0.22 / 0.78±0.23 / 0.78±0.22 / 0.78±0.22 / NS

BMI = body mass index, GFR = glomerular filtration rate, HOMA = homeostatsis model assessment, LDL = low density lipoprotein, HDL = high density lipoprotein

Supplementary Table 1B – Validation of pheno-group #2 by comparison between full sample and five 80% resampling subsets

Clinical characteristics / Full pheno-group
(N=381) / Resample 1
(N=311) / Resample 2
(N=319) / Resample 3
(N=226) / Resample 4
(N=297) / Resample 5
(N=313) / P value
Age, years / 56±12 / 57±11 / 56±12 / 55±12 / 55±12 / 56±11 / NS
Females, n(%) / 211 (55) / 175 (56) / 174 (55) / 123 (54) / 161 (54) / 180 (58) / NS
African American, n(%) / 224 (59) / 187 (60) / 185 (58) / 126 (56) / 171 (58) / 188 (60) / NS
Systolic blood pressure, mmHg / 139±24 / 139±24 / 139±24 / 137±24 / 138±23 / 139±23 / NS
Diastolic blood pressure, mmHg / 75±13 / 74±13 / 75±13 / 75±13 / 75±13 / 75±13 / NS
Coronary artery disease, n(%) / 84 (22) / 74 (24) / 75 (24) / 47 (21) / 68 (23) / 69 (22) / NS
Diabetes, n(%) / 135 (35) / 121 (39) / 118 (37) / 75 (33) / 101 (34) / 108 (35) / NS
Smoking history, n(%) / 204 (55) / 174 (57) / 164 (52) / 122 (56) / 166 (57) / 162 (53) / NS
BMI, kg/m2 / 34±9 / 35±9 / 34±9 / 33±9 / 34±9 / 34±9 / NS
GFR, ml/min/1.73m2 / 82±25 / 82±26 / 81±26 / 80±25 / 82±26 / 82±25 / NS
Glucose, mg/dL / 135±80 / 140±84 / 135±80 / 133±84 / 135±76 / 136±83 / NS
HOMA / 5.43±8.84 / 5.82±9.5 / 5.05±8.18 / 5.33±10.08 / 5.46±8.77 / 5.37±8.36 / NS
LDL cholesterol, mg/dL / 120±36 / 120±37 / 120±34 / 118±35 / 122±37 / 121±36 / NS
HDL cholesterol, mg/dL / 50±16 / 49±15 / 50±17 / 50±17 / 48±13 / 49±14 / NS
Triglycerides, mg/dL / 156±125 / 160±134 / 157±132 / 166±149 / 159±127 / 159±125 / NS
Uric acid, mg/dL / 6.42±1.83 / 6.48±1.86 / 6.4±1.85 / 6.39±1.82 / 6.51±1.84 / 6.42±1.83 / NS
Urine sodium, mmol/L / 102±51 / 100±50 / 100±50 / 102±55 / 103±51 / 103±52 / NS
Urine potassium, mmol/L / 31±18 / 32±18 / 30±17 / 30±17 / 32±19 / 33±19 / NS
Anti-hypertensive medication, n(%) / 320 (84) / 277 (89) / 268 (84) / 195 (87) / 255 (86) / 265 (85) / NS
Beta blocker / 67 (18) / 64 (21) / 60 (19) / 40 (18) / 51 (17) / 63 (20) / NS
Calcium channel blocker / 151 (40) / 126 (41) / 124 (39) / 95 (42) / 120 (40) / 123 (39) / NS
Angiotensin II receptor blocker / 15 (4) / 12 (4) / 10 (3) / 10 (4) / 9 (3) / 9 (3) / NS
Angiotensin converting enzyme inhibitor / 155 (41) / 140 (45) / 130 (41) / 85 (38) / 121 (41) / 127 (41) / NS
Thiazide diuretic / 59 (16) / 50 (16) / 48 (15) / 38 (17) / 46 (15) / 45 (14) / NS
Sympatholytic / 59 (16) / 49 (16) / 49 (15) / 40 (18) / 50 (17) / 44 (14) / NS
Statin / 52 (14) / 46 (15) / 38 (12) / 35 (16) / 41 (14) / 41 (13) / NS
Conventional echocardiographic characteristics
LV end diastolic volume, ml / 146±45 / 145±44 / 145±45 / 145±46 / 149±46 / 143±44 / NS
LV end systolic volume, ml / 67±39 / 66±38 / 67±40 / 67±41 / 69±40 / 65±36 / NS
LV jection fraction, % / 57±13 / 57±12 / 57±13 / 56±13 / 56±13 / 57±12 / NS
LV mass index, g/m2 / 99±28 / 99±28 / 98±28 / 97±30 / 100±29 / 98±28 / NS
LV hypertrophy, n(%) / 137 (39) / 114 (40) / 108 (37) / 72 (35) / 108 (40) / 113 (39) / NS
LV mass/volume ratio / 1.40±0.29 / 1.42±0.27 / 1.40±0.3 / 1.36±0.28 / 1.40±0.29 / 1.41±0.29 / NS
Left atrial dimension, cm / 3.72±0.68 / 3.74±0.65 / 3.72±0.68 / 3.66±0.69 / 3.72±0.63 / 3.72±0.69 / NS
Stroke volume, ml / 77±18 / 78±19 / 76±18 / 76±17 / 77±18 / 76±18 / NS
Cardiac index, L/min/m2 / 2.7±0.7 / 2.8±0.7 / 2.7±0.7 / 2.7±0.7 / 2.7±0.7 / 2.7±0.7 / NS
Pulse pressure/stroke volume, mmHg/ml / 0.80±0.28 / 0.79±0.28 / 0.81±0.29 / 0.81±0.28 / 0.78±0.28 / 0.81±0.28 / NS
E velocity, cm/s / 65±24 / 67±24 / 65±24 / 67±22 / 64±22 / 67±25 / NS
A velocity, cm/s / 71±24 / 74±25 / 72±24 / 68±22 / 71±23 / 72±22 / NS
E/A ratio / 0.99±0.48 / 0.99±0.52 / 0.97±0.45 / 1.03±0.45 / 0.97±0.44 / 0.99±0.52 / NS
Mitral valve deceleration time, ms / 214±74 / 207±66 / 213±76 / 219±73 / 214±77 / 209±72 / NS
Isovolumic relaxation time, ms / 85±20 / 84±20 / 85±20 / 85±20 / 85±19 / 85±21 / NS
Wall motion abnormality, n(%) / 89 (23) / 67 (22) / 74 (23) / 52 (23) / 70 (24) / 72 (23) / NS
Cardiac mechanics
Absolute longitudinal strain, % / 13±4 / 13±4 / 13±4 / 13±4 / 13±4 / 13±4 / NS
Absolute circumferential strain, % / 18±6 / 18±6 / 18±6 / 19±6 / 18±6 / 18±6 / NS
Radial strain, % / 24±12 / 24±12 / 24±12 / 25±13 / 24±12 / 24±12 / NS
e’ velocity, cm/s / 3.03±1.21 / 2.91±1.2 / 3.03±1.19 / 3.14±1.22 / 3.09±1.24 / 2.96±1.18 / NS
E/e’ ratio / 27±15 / 29±16 / 27±14 / 26±14 / 26±14 / 29±16 / NS
Early diastolic strain rate, s-1 / 0.73±0.24 / 0.72±0.25 / 0.74±0.24 / 0.75±0.25 / 0.74±0.24 / 0.73±0.24 / NS

BMI = body mass index, GFR = glomerular filtration rate, HOMA = homeostatsis model assessment, LDL = low density lipoprotein, HDL = high density lipoprotein